TY - JOUR T1 - Patiromer plus spironolactone in resistant hypertension and CKD JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 119 LP - 119 DO - 10.1136/dtb.2020.000033 VL - 58 IS - 8 A2 - , Y1 - 2020/08/01 UR - http://dtb.bmj.com/content/58/8/119.abstract N2 - Review of: Agarwal R, Rossignal P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540–1550. ER -